State-of-the-art management of urinary stone disease has shifted toward precision, prevention, and minimally invasive treatment tailored to stone burden, anatomy, and patient goals. Initial evaluation emphasizes risk stratification: noncontrast CT remains the most accurate diagnostic test, while ultrasound is favored in pregnancy and for many follow-ups to reduce radiation exposure. Acute management prioritizes symptom control with NSAIDs, antiemetics, hydration guidance (avoiding overhydration), and prompt identification of complications such as infection with obstruction, which requires urgent drainage (ureteral stent or percutaneous nephrostomy) plus antibiotics.

For ureteral stones likely to pass, medical expulsive therapy—most commonly with an alpha-blocker—may improve passage rates in selected patients, alongside shared decision-making and close reassessment. When intervention is needed, ureteroscopy with laser lithotripsy is widely used and increasingly efficient with modern digital flexible scopes, improved access sheaths, and high-power holmium:YAG or thulium fiber lasers that enable dusting and fragmentation strategies. Shock wave lithotripsy remains appropriate for select renal and proximal ureteral stones, particularly smaller, less dense stones, with attention to factors such as skin-to-stone distance and stone composition.

For larger or complex renal stones, percutaneous nephrolithotomy (PCNL) is the standard, with miniaturized approaches (mini-PCNL) reducing morbidity in appropriate cases. Advances include supine positioning options, refined tract sizes, and improved imaging guidance. Staged or combined approaches (ECIRS—endoscopic combined intrarenal surgery) can optimize clearance for complex stones.

Long-term prevention is central: stone analysis and metabolic evaluation guide individualized therapy. Evidence-based measures include increased fluid intake to achieve high urine volume, dietary sodium reduction, adequate dietary calcium (rather than restriction), moderation of animal protein, and targeted pharmacologic therapy such as thiazides, potassium citrate, or allopurinol depending on urine chemistries. Follow-up uses imaging and repeat urine studies to ensure durable risk reduction and fewer recurrences.